InMode confirmed receipt of an unsolicited takeover proposal from a CEO group at $16.20 per share. The bid values the company and reflects ongoing consolidation interest in the energy-device space, where margin-rich RF, ultrasound, and combination platforms command premium multiples.
Business & M&A
InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
CEO-led group bids for InMode; signals continued PE and strategic interest in energy-device consolidation.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Get the free Inside MedSpa brief by email
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
CEO-led group bids $16.20 per share; signals continued PE interest in energy-device consolidation.
InMode manufactures the BodyTite, FaceTite, and Morpheus8 platforms—workhorse RF and microneedling devices widely deployed in U.S. practices. A successful acquisition could trigger changes to pricing, rebate structures, service agreements, or product roadmap prioritization under new ownership. For practices, M&A activity in the device tier signals potential margin compression as acquirers seek synergies and operational leverage. Monitor the outcome and any post-close announcements regarding service, support, or pricing terms.
Source: original report ↗
Frequently asked questions
What does InMode's buyout proposal mean for medspa device pricing?
A successful acquisition could trigger changes to InMode's pricing, rebate structures, and service agreements as the new owner seeks operational synergies. Practices should expect potential margin compression and monitor post-close announcements for shifts in pricing terms or support structures.
Which InMode devices are most widely used in practices?
InMode's BodyTite, FaceTite, and Morpheus8 platforms are the primary workhorse devices deployed across U.S. practices. These RF and microneedling systems are margin-rich offerings that command premium multiples in the energy-device consolidation market.
Why are energy device companies like InMode acquisition targets?
RF, ultrasound, and combination platforms are highly profitable with strong margins, making them attractive to PE firms and strategic buyers seeking consolidation. Acquirers target these companies to achieve operational leverage and synergies across their device portfolios.
What should medspa owners do about InMode M&A activity?
Monitor the outcome of the acquisition process and any post-close announcements regarding service, support, or pricing changes. Practices should also evaluate their device contracts and consider diversifying their technology portfolio to mitigate risk from potential margin compression.
How much is the CEO group offering for InMode per share?
The unsolicited takeover proposal values InMode at $16.20 per share. This bid reflects the premium multiples that margin-rich energy-device platforms command in the current consolidation environment.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.